Organon (OGN) Return on Capital Employed (2021 - 2026)
Organon (OGN) recorded quarterly Return on Capital Employed of 10.8% in Q1 2026, up 3.35% quarter-over-quarter from 10.45% in Q4 2025, and down 179.0% on a YoY basis from 13.68% in Q1 2025.
Organon (OGN) Return on Capital Employed (2021 - 2026) Analysis & Trends
Organon's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 10.8% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 179.0% year-over-year to 10.8%; the TTM figure through Mar 2026 stood at 10.8% (down 179.0% YoY), while the FY2025 annual figure was 10.68%, up 896.0% from the prior year.
- Return on Capital Employed was 10.8% for Q1 2026 at Organon, up from 10.45% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 12.59% in Q1 2025 to a low of 21.38% in Q4 2023.
- Historically, Return on Capital Employed has averaged 5.71% across 5 years, with a median of 12.22% in 2022.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed sank 1308 bps in 2022, then soared 3302 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 14.32% in 2022, then tumbled by 49 bps to 21.38% in 2023, then surged by 130 bps to 6.43% in 2024, then soared by 63 bps to 10.45% in 2025, then gained by 3 bps to 10.8% in 2026.
- The last three Return on Capital Employed figures came in at 10.8% (Q1 2026), 10.45% (Q4 2025), and 11.15% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn | 9.49% |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn | -6.84% |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 10.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.80% |
| Dec 31, 2025 | 10.45% |
| Sep 30, 2025 | 11.15% |
| Jun 30, 2025 | 11.98% |
| Mar 31, 2025 | 12.59% |
| Dec 31, 2024 | 6.43% |
| Sep 30, 2024 | -2.18% |
| Jun 30, 2024 | -12.45% |
| Mar 31, 2024 | -20.43% |
| Dec 31, 2023 | -21.38% |
| Sep 30, 2023 | -20.53% |
| Jun 30, 2023 | -17.48% |
| Mar 31, 2023 | -16.42% |
| Dec 31, 2022 | -14.32% |
| Sep 30, 2022 | -12.83% |
| Jun 30, 2022 | -12.22% |
| Mar 31, 2022 | -10.18% |
| Dec 31, 2021 | -10.14% |
| Sep 30, 2021 | -6.89% |
| Jun 30, 2021 | -2.53% |